SEARCH

SEARCH BY CITATION

References

  • 1
    Lipton RB, Diamond S, Reed M, Diamond M, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001;41:638-645.
  • 2
    Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160.
  • 3
    Lipton RB, Reed ML, Fanning KM, Buse DC. Relationship between high frequency nausea and treatment satisfaction in episodic migraine. Headache. 2011;51(Suppl. 1):1-72.
  • 4
    Lipton RB, Buse DC, Saiers J, Fanning KM, Serrano D, Reed ML. Frequency and burden of headache-related nausea: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013;53:93-103.
  • 5
    GlaxoSmithKline. IMITREX (sumatriptan) oral tablets prescribing information. 2007.
  • 6
    Siegel SJ, O'Neill C, Dubé LM, Kaldeway P, Morris R, Jackson D, Sebree T. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007;24:1919-1926.
  • 7
    Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60:1259-1287.
  • 8
    Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD008615.
  • 9
    Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD009663.
  • 10
    Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD009665.
  • 11
    Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev. 2012;(2):CD009664.
  • 12
    Teshamae S, Monteith TS, Goadsby PJ. Acute migraine therapy: New drugs and new approaches. Curr Treat Options Neurol. 2011;13:1-14.
  • 13
    Goadsby PJ, Lipton RB, Ferrari MD. Migraine – Current understanding and treatment. N Engl J Med. 2002;346:257-270.
  • 14
    Silberstein S. Migraine symptoms: Results of a survey of self-reported migraineurs. Headache. 1995;35:387-396.
  • 15
    Pryse-Phillips W, Aubé M, Bailey P, et al. A clinical study of migraine evolution. Headache. 2006;46:1480-1486.
  • 16
    Lipton RB, Pascual J, Goadsby P. Effect of rizatriptan and other triptans on the nausea symptom of migraine: A post hoc analysis. Headache. 2001;41:754-763.
  • 17
    US Headache Consortium. US Headache Consortium guidelines. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: http://www.aan.com/Guidelines/Home/GetGuidelineContent/72 (accessed June 2013).
  • 18
    GlaxoSmithKline. IMITREX (sumatriptan) nasal spray prescribing information. 2007.
  • 19
    GlaxoSmithKline. IMITREX (sumatriptan succinate) injection prescribing information. 2008.
  • 20
    Buse DC, Serrano D, Pearlman SH, Ng-Mak DS, Reed ML, Lipton RB. Examination of unmet treatment needs among persons with episodic migraine (EM): Results of the American Migraine Prevalence and Prevention Study (AMPP). Headache. 2011;51(Suppl. 1):1-72.
  • 21
    Pierce M. Transdermal delivery of sumatriptan for the treatment of acute migraine. Neurotherapeutics. 2010;7:159-163.
  • 22
    Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Deliv. 2006;13:175-187.
  • 23
    Prausnitz MR, Langer R. Transdermal drug delivery. Nat BiotechnoI. 2008;26:1261-1268.
  • 24
    Dhote V, Bhatnagar P, Mishra PK, Mahajan SC, Mishra DK. Iontophoresis: A potential emergence of a transdermal drug delivery system. Sci Pharm. 2012;80:1-28.
  • 25
    Femenia-Font A, Balaguer-Femandez C, Merino V, Rodilla V, Lopez-Castellano A. Effect of chemical enhancers on the in vitro percutaneous absorption of sumatriptan succinate. Eur J Pharm Biopharm. 2005;61:50-55.
  • 26
    Femenia-Font A, Merino V, Rodilla V, Lopez-Castellano A. High-performance liquid chromatographic determination of sumatriptan after in vitro transdermal diffusion studies. J Pharm Biomed Anal. 2005;37:621-626.
  • 27
    Femenia-Font A, Padula C, Marra F, et al. Bioadhesive monolayer film for the in vitro transdermal delivery of sumatriptan. J Pharm Sci. 2006;95:1561-1569.
  • 28
    Balaguer-Femandez C, Femenia-Font A, Del Rio-Sancho S, Merino V, Lopez-Castellano A. Sumatriptan succinate transdermal delivery systems for the treatment of migraine. J Pharm Sci. 2008;97:2102-2109.
  • 29
    Femenia-Font A, Balaguer-Femandez C, Melina V, Lopez-Castellano A. Combination strategies for enhancing transdermal absorption of sumatriptan through skin. Lnt J Pharm. 2006;323:125-130.
  • 30
    Femenia-Font A, Balaguer-Fernandez C, Merino V, Lopez-Castellano A. Iontophoretic transdermal delivery of sumatriptan: Effect of current density and ionic strength. J Pharm Sci. 2005;94:2183-2186.
  • 31
    Patel SR, Zhong H, Sharma A, Kalia YN. In vitro and in vivo evaluation of the transdermal iontophoretic delivery of sumatriptan succinate. Eur J Pharm Biopharm. 2007;66:296-301.
  • 32
    Pierce M, Marbury T, O'Neill C, Siegel S, Du W, Sebree T. Zelrix: A novel transdermal formulation of sumatriptan. Headache. 2009;49:817-825.
  • 33
    Wilks K, Pierce M, O'Neill C, Angelov AS, Du W, Safirstein B. Pharmacokinetics of oral and transdermal sumatriptan during acute migraine and non-migraine periods: Incidence of the migraine effect (PO-55). Headache. 2010;50(Suppl. 1):S1-S83.
  • 34
    Pierce M, O'Neill C, Canas S. The pharmacokinetics of the sumatriptan iontophoretic transdermal system (NP101) in elderly versus young adults. Headache. 2011;51(Suppl. 1):1-72.
  • 35
    Freeman JC, Pierce M, Gagnon M, O'Neill C. A phase I, single-center, open-label, randomized single-dose, two way crossover study to compare the pharmacokinetics of two NP101 patch applications (sumatriptan iontophoretic transdermal system) with and without controlled heat. Presented at the 54th AHS Annual Meeting, Los Angeles, CA: June 21-24, 2012.
  • 36
    Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M. Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402-1410.
  • 37
    Schulman EA. Sumatriptan TDS for acute treatment of migraineurs with baseline nausea. Headache. 2012;52:204-212.
  • 38
    Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache. 2012;52:612-624.
  • 39
    Smith T, Pierce M, Wilks K, O'Neill C, Silberstein S. Long-term safety of the sumatriptan iontophoretic transdermal patch, NP101, for acute migraine. Presented at the 54th AHS Annual Meeting, Los Angeles, CA: June 21-24, 2012.
  • 40
    Meadows KP, Pierce M, Foster S, Jennings C, O'Neill C. Sumatriptan transdermal system (TDS) can be correctly assembled, applied, and activated during migraine attacks. Presented at the 16th Congress of the International Headache Society, Boston, MA: June 27-30, 2013.
  • 41
    Ozge A, Termine C, Antonaci F, Natriashvili S, Guidetti V, Wöber-Bingöl C. Overview of diagnosis and management of paediatric headache. Part I: Diagnosis. J Headache Pain. 2011;12:13-23.